Florbetaben
Monoclonal Gammopathy
University of ZurichSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Monoclonal Gammopathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Hellenic Society of Hematology | Phase 3 | BB |
Liraglutide University of Miami | Phase 4 | BB |
Inno-206 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | BB |
(+)-VINCRISTINE Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | B |
DARATUMUMAB Hellenic Society of Hematology | Phase 2 | B |
View all 11 →
Same molecule, other indications
Florbetaben is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →